The effect of atorvastatin on the level of inflammatory marker and right ventricular function in chronic obstructive pulmonary disease patients

The effect of atorvastatin on the level of high sensitive C reactive protein and right ventricular function in chronic obstructive pulmonary disease patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201108177356N1

Enrollment

Registered

2015-09-21

Start date

2011-04-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic obstructive pulmonary disease. ?????? ??????? ???? ??????????? ???? ????? ?? ?????? ??????? ???? ??? ????? ?????????? ?? ?????? ??????? ???? ??? ??????????

Interventions

Intervention 1: atorvastatin abidi company, 40 milligram, once a day, 3 month. Intervention 2: placebo abidi company, 40 milligram, once a day, 3 month.

Treatment - Drugs

atorvastatin abidi company, 40 milligram, once a day, 3 month

placebo abidi company, 40 milligram, once a day, 3 month

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: inclusion criteria: having stable chronic obstructive pulmonary disease for at least 3 month exclusion criteria: having coronary artery disease, using medication for reducing lipid profile; having atrial fibrilation rhythm; having active liver disease; having active infection; having malignancy; having connective tissue diseases

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Right ventricle systolic function. Timepoint: 3 months after intervention. Method of measurement: tissue duppler and speckle tracking echocardiography.	—

Secondary

Measure	Time frame
High sensitive C reactive protein. Timepoint: 3 months after intervention. Method of measurement: blood sample.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Hoorak Poorzand

Mashhad University of Medical Sciences

poorzandh@mums.ac.ir+98 51 3763 6933

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026